We aim to overcome intractable cold cancer that is refractory to existing treatments such as immune checkpoint inhibitors by developing novel combination immunotherapies utilizing T-ignite and other immunotherapies and/or molecular-targeted therapies. For this purpose, we are promoting research and development of the following series of products under the strong industry-academia collaboration, focusing on human cancers where the presence of cold tumor is a major problem.

(Next page “About us”)